Saturday 17 October 2026
Export NVCT’s income statement to Excel — free account
Nuvectis Pharma, Inc.
NVCT Healthcare Biotechnology
In the quarter to June 2026, EPS was flat and free cash flow fell 34.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
18.48
0.45
−2.38%
Follow NVCT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
1.68 | 2.27 | 2.38 | 3.07 |
+8 more quarters Free account |
Net Debt/EBITDA |
3.08 | 4.01 | 4.15 | 4.55 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.65 | 1.08 | 0.54 | 0.45 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.19) | (0.28) | (0.18) | (0.20) | |
Cash per Share |
0.94 | 1.07 | 1.45 | 1.56 | |
Shareholders Equity per Share |
0.39 | 0.61 | 0.84 | 1.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.39 | 0.61 | 0.84 | 1.06 | |
Free Cash Flow |
(4.53) | (6.51) | (3.97) | (4.49) | |
Working Capital |
9.08 | 14.22 | 18.41 | 24.01 | |
Net Current Asset Value |
9.08 | 14.22 | 18.41 | 24.01 | |
| Other line items | |||||
Quick Ratio |
1.67 | 2.25 | 2.38 | 3.06 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.19) | (0.28) | (0.18) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
5.08 | 3.84 | 4.39 | 4.35 | |
Average Assets |
24.69 | 27.77 | 25.16 | 26.45 | |
Average Common Equity |
12.98 | 17.59 | 14.06 | 17.50 |
Columns are period end dates